Reaching for Wellness in Schizophrenia

Psychiatric Clinics of North America

Volumn 30, Issue 3, 2007, Pages 453-479

  Kelly, Deanna L ^a   Boggs, Douglas L ^a   Conley, Robert R ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CANNABINOID RECEPTOR ANTAGONIST; CHLORPROMAZINE; CLOZAPINE; FAMOTIDINE; FLUOXETINE; GLIBENCLAMIDE; GLIPIZIDE; HALOPERIDOL; METFORMIN; MOOD STABILIZER; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RIMONABANT; RISPERIDONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIORIDAZINE; TOPIRAMATE; UNINDEXED DRUG; VARENICLINE; ZIPRASIDONE;

CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; EXERCISE; GENETIC PREDISPOSITION; HEALTH; HEALTH CARE SYSTEM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESPAN; LIFESTYLE; METABOLIC SYNDROME X; MORTALITY; NICOTINE REPLACEMENT THERAPY; NUTRITION; OBESITY; PATIENT MONITORING; PHYSICAL ACTIVITY; PHYSICAL DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SMOKING CESSATION; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; UNITED STATES; WEIGHT GAIN; WEIGHT REDUCTION; WELLBEING;

COMORBIDITY; CORONARY DISEASE; HEALTH BEHAVIOR; HEALTH STATUS; HUMANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 34548045553     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2007.04.003     Document Type: Review

References (198)

1. Carney C.P., Jones L., and Woolson R.F. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 21 11 (2006) 1133-1137
2. Newman S.C., and Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 36 4 (1991) 239-245
3. Hennekens C.H., Hennekens A.R., Hollar D., et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150 6 (2005) 1115-1121
4. Lambert T.J., Velakoulis D., and Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 178 Suppl (2003) S67-S70
5. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr Bull 15 1 (1989) 81-89
6. Allebeck P., and Wistedt B. Mortality in schizophrenia. A ten-year follow-up based on the Stockholm County inpatient register. Arch Gen Psychiatry 43 7 (1986) 650-653
7. Black D.W., Warrack G., and Winokur G. Excess mortality among psychiatric patients. The Iowa Record-Linkage Study. JAMA 253 1 (1985) 58-61
8. Goff D.C., Sullivan L.M., McEvoy J.P., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80 1 (2005) 45-53
9. Brown S., Birtwistle J., Roe L., et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 29 3 (1999) 697-701
10. Bachrach L.L. What we know about homelessness among mentally ill persons: an analytical review and commentary. Hosp Community Psychiatry 43 5 (1992) 453-464
11. Lublin H., Eberhard J., and Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 20 4 (2005) 183-198
12. Samele C., Patel M., Boydell J., et al. Physical illness and lifestyle risk factors in people with their first presentation of psychosis. Soc Psychiatry Psychiatr Epidemiol 42 2 (2007) 117-124
13. McCreadie R.G. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 183 (2003) 534-539
14. Elman I., Borsook D., and Lukas S.E. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31 10 (2006) 2091-2120
15. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 35 Suppl (1999) S93-S100
16. Dickey B., Normand S.L., Weiss R.D., et al. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv 53 7 (2002) 861-867
17. Vanina Y., Podolskaya A., Sedky K., et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 53 7 (2002) 842-847
18. Kilbourne A.M., McCarthy J.F., Welsh D., et al. Recognition of co-occurring medical conditions among patients with serious mental illness. J Nerv Ment Dis 194 8 (2006) 598-602
19. Folsom D.P., McCahill M., Bartels S.J., et al. Medical comorbidity and receipt of medical care by older homeless people with schizophrenia or depression. Psychiatr Serv 53 11 (2002) 1456-1460
20. Muck-Jorgensen P., Mors O., Mortensen P.B., et al. The schizophrenic patient in the somatic hospital. Acta Psychiatr Scand Suppl 407 (2000) 96-99
21. Newcomer J.W., Nasrallah H.A., and Loebel A.D. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 24 5 Suppl 1 (2004) S1-S6
22. Buckley P.F., Miller D.D., Singer B., et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 79 2-3 (2005) 281-288
23. Mackin P., Watkinson H.M., and Young A.H. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48 2 (2005) 215-221
24. Nasrallah H.A., Meyer J.M., Goff D.C., et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86 1-3 (2006) 15-22
25. Weissman E.M., Zhu C.W., Schooler N.R., et al. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. J Clin Psychiatry 67 9 (2006) 1323-1326
26. Himelhoch S., Lehman A., Kreyenbuhl J., et al. Prevalence of chronic obstructive pulmonary disease among those with serious mental illness. Am J Psychiatry 161 12 (2004) 2317-2319
27. Kreyenbuhl J., Dickerson F.B., Medoff D.R., et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis 194 6 (2006) 404-410
28. de Leon J., Dadvand M., Canuso C., et al. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 152 3 (1995) 453-455
29. de Leon J., and Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76 2-3 (2005) 135-157
30. Olincy A., Harris J.G., Johnson L.L., et al. Proof-of-concept trial of an {alpha}7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63 6 (2006) 630-638
31. Harris E.C., and Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 173 (1998) 11-53
32. Joukamaa M., Heliovaara M., Knekt P., et al. Mental disorders and cause-specific mortality. Br J Psychiatry 179 (2001) 498-502
33. Filik R., Sipos A., Kehoe P.G., et al. The cardiovascular and respiratory health of people with schizophrenia. Acta Psychiatr Scand 113 4 (2006) 298-305
34. Hole D.J., Watt G.C.M., Davey-Smith G., et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 313 7059 (1996) 711-715
35. Shopland D.R. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect 103 Suppl 8 (1995) 131-142
36. Grinshpoon A., Barchana M., Ponizovsky A., et al. Cancer in schizophrenia: is the risk higher or lower?. Schizophr Res 73 2-3 (2005) 333-341
37. Sokal J., Messias E., Dickerson F.B., et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 192 6 (2004) 421-427
38. Hunninghake D.B. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 1 (2005) 44-49
39. Critchley J.A., and Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 290 1 (2003) 86-97
40. Hedley A.A., Ogden C.L., Johnson C.L., et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291 23 (2004) 2847-2850
41. Pi-Sunyer F.X. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 10 Suppl 2 (2002) 97S-104S
42. Lapidus L., Bengtsson C., Larsson B., et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed) 289 6454 (1984) 1257-1261
43. Ohlson L.O., Larsson B., Svardsudd K., et al. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 34 10 (1985) 1055-1058
44. Calle E.E., Thun M.J., Petrelli J.M., et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341 15 (1999) 1097-1105
45. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 14 (2002) 1723-1727
46. Homel P., Casey D., and Allison D.B. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 55 3 (2002) 277-284
47. Wirshing D.A. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 65 Suppl 18 (2004) 13-26
48. DeLeon A., Patel N.C., and Crismon M.L. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26 5 (2004) 649-666
49. Nonogaki K., Strack A.M., Dallman M.F., et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 4 10 (1998) 1152-1156
50. Wirshing D.A., Wirshing W.C., Kysar L., et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60 6 (1999) 358-363
51. Kim S.F., Huang A.S., Snowman A.M., et al. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104 9 (2007) 3456-3459
52. Kroeze W.K., Hufeisen S.J., Popadak B.A., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28 3 (2003) 519-526
53. Baptista T., Lacruz A., Meza T., et al. Antipsychotic drugs and obesity: is prolactin involved?. Can J Psychiatry 46 9 (2001) 829-834
54. Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 11 (1999) 1686-1696
55. Henderson D.C., Cagliero E., Gray C., et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157 6 (2000) 975-981
56. Goff D.C., Cather C., Evins A.E., et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 66 2 (2005) 183-194 [quiz: 147, 273-4]
57. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 12 (2005) 1209-1223
58. Zipursky R.B., Gu H., Green A.I., et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 187 (2005) 537-543
59. Martin A., and L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 11 3 (2002) 129-133
60. Kelly D.L., Conley R.R., Love R.C., et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8 3 (1998) 151-159
61. Shaw J.A., Lewis J.E., Pascal S., et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11 4 (2001) 415-424
62. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 19 (2001) 2486-2497
63. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005 (2005), U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta (GA). http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf Available at:
64. Mayor S. Diabetes affects nearly 6% of the world's adults. BMJ 333 7580 (2006) 1191
65. Chan J.M., Rimm E.B., Colditz G.A., et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17 9 (1994) 961-969
66. Colditz G.A., Willett W.C., Rotnitzky A., et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122 7 (1995) 481-486
67. Sullivan P.W., Morrato E.H., Ghushchyan V., et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care 28 7 (2005) 1599-1603
68. Lamberti J.S., Crilly J.F., Maharaj K., et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 65 5 (2004) 702-706
69. Susce M.T., Villanueva N., Diaz F.J., et al. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 66 2 (2005) 167-173
70. Dixon L., Weiden P., Delahanty J., et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26 4 (2000) 903-912
71. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160 2 (2003) 284-289
72. Henderson D.C., Cagliero E., Copeland P.M., et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62 1 (2005) 19-28
73. Arranz B., Rosel P., Ramirez N., et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65 10 (2004) 1335-1342
74. Ramaswamy K., Masand P.S., and Nasrallah H.A. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry 18 3 (2006) 183-194
75. Gianfrancesco F., White R., Wang R.H., et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 23 4 (2003) 328-335
76. Caro J.J., Ward A., Levinton C., et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63 12 (2002) 1135-1139
77. Lambert B.L., Chou C.H., Chang K.Y., et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf 14 6 (2005) 417-425
78. Lambert M.T., Copeland L.A., Sampson N., et al. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry 30 5 (2006) 919-923
79. Lambert B.L., Cunningham F.E., Miller D.R., et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol 164 7 (2006) 672-681
80. Guo J.J., Keck Jr. P.E., Corey-Lisle P.K., et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy 27 1 (2007) 27-35
81. Sacchetti E., Turrina C., Parrinello G., et al. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol 20 1 (2005) 33-37
82. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
83. Stamler J., Wentworth D., and Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256 20 (1986) 2823-2828
84. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 4A (1998) 7B-12B
85. Meyer J.M., and Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70 1 (2004) 1-17
86. Clark M.L., and Johnson P.C. Amenorrhea and elevated level of serum cholesterol produced by a trifluoromethylated phenothiazine (SKF 5354-A). J Clin Endocrinol Metab 20 (1960) 641-646
87. Clark M.L., Ray T.S., Paredes A., et al. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosom Med 29 6 (1967) 634-642
88. Mefferd Jr. R.B., Labrosse E.H., Gawienowski A.M., et al. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. J Nerv Ment Dis 127 2 (1958) 167-179
89. Vaisanen K., Rimon R., Raisanen P., et al. A controlled double-blind study of haloperidol versus thioridazine in the treatment of restless mentally subnormal patients. Serum levels and clinical effects. Acta Psychiatr Belg 79 6 (1979) 673-685
90. Shafique M., Khan I.A., Akhtar M.H., et al. Serum lipids and lipoproteins in schizophrenic patients receiving major tranquilizers. J Pak Med Assoc 38 10 (1988) 259-261
91. Atmaca M., Kuloglu M., Tezcan E., et al. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 60 1 (2003) 99-100
92. Atmaca M., Kuloglu M., Tezcan E., et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64 5 (2003) 598-604
93. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63 5 (2002) 425-433
94. Weiden P.J., Daniel D.G., Simpson G., et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23 6 (2003) 595-600
95. Kingsbury S.J., Fayek M., Trufasiu D., et al. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 62 5 (2001) 347-349
96. Olfson M., Marcus S.C., Corey-Lisle P., et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 163 10 (2006) 1821-1825
97. Itoh T., Horie S., Takahashi K., et al. An evaluation of various indices of body weight change and their relationship with coronary risk factors. Int J Obes Relat Metab Disord 20 12 (1996) 1089-1096
98. Baptista T., Lacruz A., Angeles F., et al. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 34 6 (2001) 223-231
99. Meyer J.M. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 62 Suppl 27 (2001) 27-34 [discussion: 40-1]
100. Meyer J.M. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21 4 (2001) 369-374
101. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 19 (2003) 2560-2572
102. Henderson D.C., Daley T.B., Kunkel L., et al. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 65 5 (2004) 686-689
103. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 12 (1988) 1595-1607
104. Haffner S.M., Valdez R.A., Hazuda H.P., et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41 6 (1992) 715-722
105. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 4 (2001) 683-689
106. Trevisan M., Liu J., Bahsas F.B., et al. Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 148 10 (1998) 958-966
107. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 112 17 (2005) 2735-2752
108. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 3 (2002) 356-359
109. Kato M.M., Currier M.B., Gomez C.M., et al. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion. J Clin Psychiatry 6 2 (2004) 74-77
110. Correll C.U., Frederickson A.M., Kane J.M., et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 67 4 (2006) 575-583
111. De Hert M.A., van Winkel R., Van Eyck D., et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83 1 (2006) 87-93
112. Meyer J., Loh C., Leckband S.G., et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 12 1 (2006) 5-10
113. McEvoy J.P., Meyer J.M., Goff D.C., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80 1 (2005) 19-32
114. Bobes J., Arango C., Aranda P., et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res 90 1-3 (2007) 162-173
115. Saari K.M., Lindeman S.M., Viilo K.M., et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 66 5 (2005) 559-563
116. Heiskanen T., Niskanen L., Lyytikainen R., et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64 5 (2003) 575-579
117. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68 Suppl 1 (2007) 20-27
118. Fiore M.C., Hatsukami D.K., and Baker T.B. Effective tobacco dependence treatment. JAMA 288 14 (2002) 1768-1771
119. Dalack G.W., and Meador-Woodruff J.H. Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia. Nicotine Tob Res 1 1 (1999) 53-57
120. George T.P., Ziedonis D.M., Feingold A., et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 157 11 (2000) 1835-1842
121. Tidey J.W., O'Neill S.C., and Higgins S.T. Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Exp Clin Psychopharmacol 10 3 (2002) 241-247
122. Chou K.R., Chen R., Lee J.F., et al. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud 41 3 (2004) 321-330
123. Hartman N., Leong G.B., Glynn S.M., et al. Transdermal nicotine and smoking behavior in psychiatric patients. Am J Psychiatry 148 3 (1991) 374-375
124. Addington J., el-Guebaly N., Campbell W., et al. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 155 7 (1998) 974-976
125. Ziedonis D.M., and George T.P. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 23 2 (1997) 247-254
126. Evins A.E., Cather C., Rigotti N.A., et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry 65 3 (2004) 307-311 [quiz: 452-3]
127. George T.P., Vessicchio J.C., Termine A., et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 52 1 (2002) 53-61
128. Evins A.E., Cather C., Deckersbach T., et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 25 3 (2005) 218-225
129. Weiner E., Ball M.P., Summerfelt A., et al. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 158 4 (2001) 635-637
130. Reus V.I., Obach R.S., Coe J.W., et al. Varenicline: new treatment with efficacy in smoking cessation. Drugs Today (Barc) 43 2 (2007) 65-75
131. Nides M., Oncken C., Gonzales D., et al. Smoking cessation with varenicline, a selective {alpha}4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166 15 (2006) 1561-1568
132. Kroon L.A. Drug interactions and smoking: raising awareness for acute and critical care providers. Crit Care Nurs Clin North Am 18 1 (2006) 53-62 xii
133. Loh C., Meyer J.M., and Leckband S.G. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 18 1 (2006) 23-31
134. Kwon J.S., Choi J.S., Bahk W.M., et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 67 4 (2006) 547-553
135. Littrell K.H., Hilligoss N.M., Kirshner C.D., et al. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 35 3 (2003) 237-241
136. Brar J.S., Ganguli R., Pandina G., et al. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 66 2 (2005) 205-212
137. Evans S., Newton R., and Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry 39 6 (2005) 479-486
138. Weber M., and Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 83 1 (2006) 95-101
139. Daniel D.G., Zimbroff D.L., Potkin S.G., et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20 5 (1999) 491-505
140. Keck Jr. P., Buffenstein A., Ferguson J., et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 140 2 (1998) 173-184
141. Hirsch S.R., Kissling W., Bauml J., et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 63 6 (2002) 516-523
142. Gupta S., Masand P.S., Virk S., et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 70 1 (2004) 57-62
143. Meyer J.M., Pandina G., Bossie C.A., et al. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 27 12 (2005) 1930-1941
144. Essock S.M., Covell N.H., Davis S.M., et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 163 12 (2006) 2090-2095
145. Henderson D.C., Copeland P.M., Daley T.B., et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 162 5 (2005) 954-962
146. Henderson D.C., Fan X., Copeland P.M., et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 115 2 (2007) 101-105
147. Kim J.H., Yim S.J., and Nam J.H. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 82 1 (2006) 115-117
148. Ko Y.H., Joe S.H., Jung I.K., et al. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28 4 (2005) 169-175
149. Poyurovsky M., Fuchs C., Pashinian A., et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl) (2007)
150. Poyurovsky M., Isaacs I., Fuchs C., et al. Attenuating effect of reboxetine on appetitie and weight gain in olanzapine-treated schizophrenia patients: a double-blind, placebo-controlled study. Psychopharmacology 192 3 (2007) 441-448
151. Deberdt W., Winokur A., Cavazzoni P.A., et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 15 1 (2005) 13-21
152. Graham K.A., Gu H., Lieberman J.A., et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162 9 (2005) 1744-1746
153. Klein D.J., Cottingham E.M., Sorter M., et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 163 12 (2006) 2072-2079
154. Baptista T., Martinez J., Lacruz A., et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 51 3 (2006) 192-196
155. Cavazzoni P., Tanaka Y., Roychowdhury S.M., et al. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 13 2 (2003) 81-85
156. Assuncao S.S., Ruschel S.I., Rosa Lde C., et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr 28 4 (2006) 270-276
157. Atmaca M., Kuloglu M., Tezcan E., et al. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 18 6 (2003) 457-461
158. Atmaca M., Kuloglu M., Tezcan E., et al. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol 19 1 (2004) 37-40
159. Poyurovsky M., Pashinian A., Gil-Ad I., et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 159 6 (2002) 1058-1060
160. Bustillo J.R., Lauriello J., Parker K., et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 28 3 (2003) 527-529
161. Poyurovsky M., Tal V., Maayan R., et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 14 4 (2004) 332-336
162. Van Gaal L.F., Rissanen A.M., Scheen A.J., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 9468 (2005) 1389-1397
163. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 7 (2006) 761-775
164. Hill M.N., and Gorzalka B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav Pharmacol 16 5-6 (2005) 333-352
165. Gadde K.M., and Allison D.B. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 114 9 (2006) 974-984
166. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 18 (2001) 1343-1350
167. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 6 (2002) 393-403
168. Franz M.J., Bantle J.P., Beebe C.A., et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 26 Suppl 1 (2003) S51-S61
169. Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 90001 (2003) S33-S50
170. Standards of medical care in diabetes. Diabetes Care 28 Suppl 1 (2005) S4-S36
171. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 854-865
172. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 837-853
173. Costa J., Borges M., David C., et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332 7550 (2006) 1115-1124
174. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317 7160 (1998) 703-713
175. Melkersson K., and Hulting A.-L. Recovery from new-onset diabetes in a schizophrenic man after withdrawal of Olanzapine. Psychosomatics 43 1 (2002) 67-70
176. Rigalleau V., Gatta B., Bonnaud S., et al. Diabetes as a result of atypical anti-psychotic drugs-a report of three cases. Diabet Med 17 6 (2000) 484-486
177. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
178. Snow V., Aronson M.D., Hornbake E.R., et al. The Clinical Efficacy Assessment Subcommittee of the American College of Pysicians. lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 140 8 (2004) 644-649
179. Arauz-Pacheco C., Parrott M.A., and Raskin P. Hypertension management in adults with diabetes. Diabetes Care 27 Suppl 1 (2004) S65-S67
180. Hayward R.A., Hofer T.P., and Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 145 7 (2006) 520-530
181. Caniato R.N., Alvarenga M.E., and Garcia-Alcaraz M.A. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust N Z J Psychiatry 40 8 (2006) 691-697
182. De Hert M., Kalnicka D., van Winkel R., et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 67 12 (2006) 1889-1896
183. Hanssens L., De Hert M., Kalnicka D., et al. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol 22 1 (2007) 43-49
184. Appel L.J., Moore T.J., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336 16 (1997) 1117-1124
185. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 6 (2003) 1206-1252
186. Barzilay J.I., Davis B.R., Cutler J.A., et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 166 20 (2006) 2191-2201
187. Baymiller S.P., Ball P., McMahon R.P., et al. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 59 1 (2003) 49-57
188. Lehman A.F., Lieberman J.A., Dixon L.B., et al. Practice guideline for the treatment of patients with schizophrenia. 2nd edition. Am J Psychiatry 161 2 Suppl (2004) 1-56
189. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27 2 (2004) 596-601
190. Marder S.R., Essock S.M., Miller A.L., et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161 8 (2004) 1334-1349
191. Schizophrenia and diabetes 2003: expert consensus meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry Suppl 47 (2004) S112-S114
192. Woo V., Harris S., and Houlden R. Canadian Diabetes Association position paper: antipsychotic medications and associated risks of weight gain and diabetes. Canadian Journal of Diabetes 29 2 (2005) 111-112
193. Lambert T.J., and Chapman L.H. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 181 10 (2004) 544-548
194. Cohn T.A., and Sernyak M.J. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 51 8 (2006) 492-501
195. van Winkel R., De Hert M., Van Eyck D., et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 67 10 (2006) 1493-1500
196. Citrome L., and Yeomans D. Do guidelines for severe mental illness promote physical health and well-being?. J Psychopharmacol 19 6 Suppl (2005) 102-109
197. Leucht S., and Fountoulakis K. Improvement of the physical health of people with mental illness. Curr Opin Psychiatry 19 4 (2006) 411-412
198. Druss B.G., Rohrbaugh R.M., Levinson C.M., et al. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry 58 9 (2001) 861-868